Topical antibiotic treatment of impetigo with tetracycline

Journal of Dermatology

Volumn 32, Issue 10, 2005, Pages 788-792

  Kuniyuki, Shuichi ^a   Nakano, Kazuhito ^a   Maekawa, Naoki ^a   Suzuki, Shinsuke ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Impetigo; MRSA; Tetracycline; Treatment

Indexed keywords

ANTIBIOTIC AGENT; CEFDINIR; FOSFOMYCIN; MINOCYCLINE; OXYTETRACYCLINE; TETRACYCLINE;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BULLOUS SKIN DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; IMPETIGO; INFANT; MALE; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS;

EID: 28244474542     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2005.tb00846.x     Document Type: Article

References (26)

1. Baltimore RS: Treatment of impetigo: A review, Pediatr Infect Dis, 4: 597-601, 1985.
2. Espersen F: Resistance to antibiotics used in dermatological practice, Br J Dermatol, 139: 4-8, 1998.
3. Hay RJ, Adriaans BM: Bacterial infections, in Champion RH, Burton JL, Ebling FJG (eds): Rook/Wilkinson/Ebling: Textbook of Dermatology, 6th ed, Blackwell, Oxford, 1998, pp 1109-1111.
4. Brown J, Shriner DL, Schwartz RA, Janniger CK: Impetigo: An update (Review), Int J Dermatol, 42: 251-255, 2003.
5. Boyce JM: Patterns of methicillin-resistant Staphylococcus aureus prevalence, Infect Control Hospital Epidemiol, 12: 79-82, 1991.
6. Mertz PM, Marshal DA, Eaglestein WH, et al: Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy, Arch Dermatol, 125: 1069-1073, 1989.
7. Dagan R, Bar-David Y: Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: Implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains, Antimicrob Agents Chemother, 36: 287-290, 1992.
8. Ells LD, Mertz PM, Piovanetti Y, et al: Topical antibiotic treatment of impetigo with mupirocin, Arch Dermatol, 122: 1273-1276, 1986.
9. McLinn S: A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo, J Am Acad Dermatol, 22: 883-885, 1990.
10. Boukes FS, van der Burgh JJ, Nijman FC, et al: NHG-standaard bacteriële huidinfecties [Dutch College of General Practitioners' guideline on bacterial skin infections], Huisarts Wet, 41: 427-437, 1999.
11. Morley PAR, Munot LD: A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis, Curr Med Res Opin, 11: 142-148, 1988.
12. Tveten Y, Andrew J, Kristiansen B-E: A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway, J Antimicrob Chemother, 50: 873-876, 2002.
13. Wong KS, Lim KB, Tham SN, et al: Comparative double-blinded study between mupirocin and tetracycline ointments for treating skin infections, Sing Med J, 30: 380-383, 1989.
14. Wainscott G, Huskisson SC: A comparative study of Bactroban ointment and chlortetracycline cream, in Dobson RL, Leyden JJ, Noble WC, Price JD (eds): Excerpta Medica Current Clinical Practice Series, Bactroban (Mupirocin) Amsterdam, Amsterdam, 16, 1985, p 137.
15. Sase H, Yamazaki K, Kosenda T, et al: Studies on coagulase type and antibiotic sensitivities of Staphylococcus aureus isolated from impetigo contagiosa, Rinsho-Hifuka, 48: 973-976, 1994. (in Japanese)
16. Miida H, Uanaka E, Ito M: Clicinal study of impetigo contagiosa caused by methicillin-resistant Staphylococcus aureus, Rinsho-Hifuka, 55: 1005-1007, 2001. (in Japanese)
17. Iijima S, Nanno Y, Takeda S, et al: Frequency of infection caused by Staphylococcus aureus and its antimicrobial susceptibility in dermatology compared with other clinics, Nishinihon-J Dermatol, 64: 344-350, 2002.
18. DeNeeling AJ, van Leeuwen WJ, Schouls LM, et al: Resistance of staphylococci in the Netherlands: Surveillance by an electronic network during 1989-1995, J Antimicrob chemother, 41: 93-101, 1998.
19. Rogers M, Dorman DC, Gapes M, Ly J: A three-year study of impetigo in Sydney, Med J Aust, 147: 63-65, 1987.
20. George A, Rubin G: A systematic review and meta-analysis of treatments for impetigo, Br J Gen Pract, 53: 480-487, 2003.
21. Britton JW, Fajardo JE, Krafte-Jacobs B: Comparison of mupirocin and erythromycin in the treatment of impetigo, J Pediatr, 117: 827-829, 1990.
22. Gilbert M: Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections, J Am Acad Dermatol, 11: 142-148, 1989.
23. Bass JW, Chan DS, Creamer KM, et al: Comparison of oral cephalexin, topical mupirocin, and topical bacitracin for treatment of impetigo, Pediatr Inf Dis J, 16: 708-709, 1997.
24. Akiyama H, Abe Y, Shimoe K, et al: Changes of susceptibilities of Staphylococcus aureus during topical application on experimental staphylococcal skin infection in mice, Jpn J Dermatol, 103; 643-648, 1993. (in Japanese)
25. Nishijima S, Ohshima S, Higashida T, et al: Antimicrobial resistance of Staphylococcus aureus isolated from impetigo patients between 1994 and 2000, Int J Dermatol, 42: 23-25, 2003.
26. Booth JH, Benrimoj SI: Mupirocin in the treatment of impetigo (Review), Int J Dermatol, 31: 1-9, 1992.